These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 7168451)

  • 1. Antitrust and third party insurers.
    Heitler G
    Am J Law Med; 1982; 8(3):251-70. PubMed ID: 7168451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How can PPOs control prices without violating antitrust laws?
    Fried JM
    Hosp Prog; 1984 Mar; 65(3):34-7. PubMed ID: 10265221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitrust and health care: provider controlled health plans and the Maricopa decision.
    Weller CD
    Am J Law Med; 1982; 8(3):223-49. PubMed ID: 6897759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing antitrust liability after Maricopa.
    Walsh JH; Feller H
    GHAA J; 1986; 7(2):57-74. PubMed ID: 10280126
    [No Abstract]   [Full Text] [Related]  

  • 5. Recent supreme court antitrust rulings in health care.
    Podell LB
    Am J Hosp Pharm; 1983 Apr; 40(4):639-41. PubMed ID: 6846375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are PPOs a competitive force or antitrust risk?
    Enders RJ
    Healthc Financ Manage; 1986 May; 40(5):52-60. PubMed ID: 10276171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitrust implications of joint negotiations with third party payers.
    Rainer JM
    Top Health Care Financ; 1986; 13(2):79-85. PubMed ID: 3810649
    [No Abstract]   [Full Text] [Related]  

  • 8. The development of preferred provider organizations and its antitrust implications.
    Maram BS
    J Med Pract Manage; 1985 Oct; 1(2):130-5. PubMed ID: 10281825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost containment in the health care field and the antitrust laws.
    Shapiro DI
    Am J Law Med; 1982; 7(4):425-35. PubMed ID: 7102679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitrust charges fail to slow PPA action by insurer.
    Burda D
    Hospitals; 1986 Apr; 60(8):68-70. PubMed ID: 3754236
    [No Abstract]   [Full Text] [Related]  

  • 11. Antitrust and the new competition in health care: excerpts.
    Ginsburg DH
    Med Prod Sales; 1986 Apr; 17(4):39-42. PubMed ID: 10276459
    [No Abstract]   [Full Text] [Related]  

  • 12. Provider-sponsored ADSs: reducing antitrust liability after Maricopa.
    Walsh JH; Feller H
    Spec Law Dig Health Care (Mon); 1985 Apr; 7(2):5-25. PubMed ID: 10270877
    [No Abstract]   [Full Text] [Related]  

  • 13. Physicians and PPOs: antitrust lessons from Maricopa.
    Finke RF; Gary M
    Hosp Med Staff; 1983 Jul; 12(7):10-5. PubMed ID: 10278175
    [No Abstract]   [Full Text] [Related]  

  • 14. An economic analysis of the Maricopa decision.
    Goldberg LG; Greenberg W
    Health Matrix; 1987; 5(2):26-30. PubMed ID: 10283416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitrust law and collective physician negotiations with third parties: the relative value guide object lesson.
    Pfizenmayer RF
    J Health Polit Policy Law; 1982; 7(1):128-62. PubMed ID: 7108165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physicians and PPOs: antitrust considerations in setting fees.
    Fried JM; Romansky MA
    Internist; 1984 Apr; 25(4):18, 32. PubMed ID: 10266538
    [No Abstract]   [Full Text] [Related]  

  • 17. Establishing physician networks within evolving antitrust guidelines.
    Retchin TN; Retchin SM
    Clin Perform Qual Health Care; 1997; 5(3):140-5. PubMed ID: 10169186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preferred provider organizations: antitrust aspects and implications for the hospital industry.
    Batavia AI
    Am J Law Med; 1984; 10(2):169-88. PubMed ID: 6528879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitrust implications of chiropractic Peer Review Committees.
    Volper V
    Am J Law Med; 1982; 8(1):45-68. PubMed ID: 7124747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimizing antitrust and corporate liability risks.
    Weissburg C
    Health Prog; 1987 Apr; 68(3):68-73, 90. PubMed ID: 10282282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.